The therapeutic effect of MANF in the MPTP/MPP+-induced model of Parkinson’s disease
Objective: To observe therapeutic effect of MANF in the attenuation of neurotoxin MPTP/MPP+-induced model of Parkinson's disease Background: Mesencephalic astrocyte-derived neurotrophic factor (MANF) is a…Parkinsonian Features in a Cohort of Gaucher’s Disease (GD) Patients and Relatives.
Objective: to investigate the prevalence and clinical features of parkinsonism in a cohort of 21 GD patients and their relatives. Background: GD is a lysosomal…Pure ATXN10 repeat expansion causes Parkinson’s disease
Objective: Clinical and genetic characterization of a multigenerational family with spinocerebellar ataxia type 10 (SCA10) and parkinsonism. Background: Pentanucleotide repeat expansions of ATTCT in intron…Short term effects of bilateral STN DBS on psychiatric profile in Parkinson’s disease
Objective: We intend to look into the effects of bilateral STN DBS on Psychiatric profile of Parkinson’s patients. Background: Parkinson’s disease is a well-known degenerative…Young Onset Parkinson’s Disease (YOPD): A different disease entity?
Objective: To study the clinical manifestations of YOPD and Late Onset Parkinson’s Disease (LOPD) patients Background: Parkinson’s disease (PD) is a neurodegenerative disease commonly affecting…Determinants of balance confidence and concern about falling in people with Parkinson’s disease
Objective: To identify factors that contribute to balance confidence and concern about falling in people with Parkinson’s disease (PD). Background: Reduced balance confidence and greater…Comorbid Normal Pressure Hydrocephalus with Parkinson’s disease: a call for clinical awareness
Objective: To examine a case of comorbid normal pressure hydrocephalus (NPH) with Parkinson’s Disease (PD). Background: PD and NPH are the most common high level…Time to retreatment with botulinum toxin A in upper limb spasticity management: initial data from the Upper Limb International Spasticity (ULIS)-III study
Objective: The ongoing ULIS-III study aims to describe real-life clinical practice and assess patient‑centered goal attainment with integrated upper limb spasticity (ULS) management that includes…Levodopa responsiveness in Parkinson’s disease is significantly impaired in those with diabetes and increased vascular risk.
Objective: To define variation in L-dopa response in recent onset PD. Background: L-Dopa responsiveness is a defining feature of Parkinson’s disease (PD), but the degree…Effect of Droxidopa Treatment on Fear of Falling in Patients With Neurogenic Orthostatic Hypotension: Clinical Trial and “Real World” Results
Objective: To assess the impact of droxidopa on fear of falling in patients with symptomatic neurogenic orthostatic hypotension (nOH) in 2 studies. Background: nOH results…
- « Previous Page
- 1
- …
- 119
- 120
- 121
- 122
- 123
- …
- 155
- Next Page »